Mingzhi Zhang

34PUBLICATIONS
39CO-AUTHORS
Molecular targetsHaematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Chemotherapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (34)

|Sep 18, 2026
Synergistic Anti-Tumor Effect of Chidamide and Linperlisib on Natural Killer/T-Cell Lymphoma by Inhibiting PI3K/AKT/mTOR Pathway.

|May 28, 2026
LCP2 mediates SUV39H1-driven cellular senescence-related chemoresistance in natural killer/T-cell lymphoma.

|May 13, 2026
Prolonged intratumoral treatment with TLR7/8 agonist R848 regulates the tumor immune microenvironment resulting in enhanced antitumor activity.

|Mar 09, 2026
Fotemustine-containing chemotherapy suggests lower toxicity with comparable efficacy versus high-dose methotrexate-based regimens: a retrospective cohort analysis.

Xudong Zhang, Wanyue Zhao, Wenhua Wang

|Jan 04, 2026
A first-line regimen combining Bruton's tyrosine kinase and programmed cell death protein-1 inhibitors with chemotherapy excluding methotrexate achieves high response rates in primary central nervous system lymphoma.

Wanyue Zhao, Ling Li, Xiaorui Fu

|Dec 09, 2025
GNAQ inhibits tumorigenesis via the ARHGEF25-mediated RHOA pathway in NK/T-cell lymphoma.

Yuyang Gao, Zihe Zhang, Yue Song

Pageof 6

Frequent Collaborators

3 joint publications

Lei Zhang

3 joint publications

Xudong Zhang

3 joint publications

Qingjiang Chen

2 joint publications

Wanyue Zhao